AIDS
MCID: ACQ007
MIFTS: 60

Acquired Immunodeficiency Syndrome (AIDS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Acquired Immunodeficiency Syndrome

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 11 43 14 71
Acquired Immune Deficiency Syndrome 11 2 14
Aids 11 47
Acquired Immunodeficiency Due to Protein Loss 33
Acquired Immune Deficiency 11
Acquired Immunodeficiency 58

Classifications:

Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 11 DOID:635
MeSH 43 D000163
NCIt 49 C2851
SNOMED-CT 68 62479008
ICD10 31 B20
UMLS via Orphanet 72 C0001175
Orphanet 58 ORPHA310050
UMLS 71 C0001175

Summaries for Acquired Immunodeficiency Syndrome

CDC: 2 HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

MalaCards based summary: Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to human immunodeficiency virus type 1 and aids dementia complex. An important gene associated with Acquired Immunodeficiency Syndrome is HCP5 (HLA Complex P5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ethambutol and Pyrazinamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone marrow, and related phenotypes are neoplasm and endocrine/exocrine gland

Disease Ontology: 11 A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per microliter of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

Related Diseases for Acquired Immunodeficiency Syndrome

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2617)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 33.2 ITIH4 IL2 IL10 IFNG HLA-B CD4
2 aids dementia complex 32.5 TNF ITIH4 B2M
3 oral hairy leukoplakia 32.5 ITIH4 IL10 CD4
4 dementia 32.5 TNF ITIH4 IL6 IL1B CCR5
5 ascaris lumbricoides infection 32.5 IL10 CD4 ALB
6 good syndrome 32.4 TNF IL6 IL10 CD4
7 pneumocystosis 32.3 TNF IL6 IL2 IL10 IFNG CD4
8 toxoplasmosis 32.3 TNF IL6 IL1B IL10 IFNG CCR5
9 immune system disease 32.2 TNF IL6 IL2 IL1B IL10 CD4
10 immune deficiency disease 32.1 TNF RN7SK NEAT1 ITIH4 IL6 IL2
11 histoplasmosis 32.1 TNF IFNG HLA-B CD4
12 cryptococcosis 32.1 TNF IL10 IFNG CSF2 CD4
13 human cytomegalovirus infection 32.1 TNF IL6 IL10 CD4
14 cytomegalovirus retinitis 32.0 TNF IL10 IFNG HLA-B CSF2 CD4
15 autonomic nervous system disease 32.0 TNF IL6 IL1B ALB
16 candidiasis 31.9 TNF IL6 IL2 IL1B IL10 IFNG
17 macs syndrome 31.9 TNF IL10 IFNG IFNA1 CD4
18 progressive multifocal leukoencephalopathy 31.9 TNF IL2 CD4 CCR5
19 pneumonia 31.9 TNF IL6 IL1B IL10 IFNG CSF2
20 encephalitis 31.8 TNF ITIH4 IL6 IL1B IL10 IFNA1
21 cryptosporidiosis 31.8 TNF IFNG CD4
22 viral infectious disease 31.8 TNF ITIH4 IL6 IL2 IL1B IL10
23 oral candidiasis 31.8 IL6 CD4 B2M
24 cryptococcal meningitis 31.8 TNF IL6 IL2 IL10 IFNG CSF2
25 meningitis 31.8 TNF IL6 IL2 IL1B IL10 IFNG
26 esophagitis 31.7 TNF IL6 IL1B IL10
27 diarrhea 31.7 TNF IL6 IL2 IL1B IL10 IFNG
28 aspergillosis 31.7 TNF IL6 IL1B IL10 IFNG CSF2
29 lymphopenia 31.7 IL6 IL2 IL10 IFNG
30 vasculitis 31.7 TNF IL6 IL1B IL10 HLA-B
31 spinal cord disease 31.6 TNF IL6 IL10 CD4 ALB
32 chickenpox 31.6 TNF IL6 IL2 IL1B IL10 IFNG
33 retinal detachment 31.6 TNF IL6 IL10 IFNG
34 syphilis 31.6 TNF CD4 CCR5 B2M ALB
35 miliary tuberculosis 31.6 TNF IL2 IL10 IFNG CD4 ALB
36 herpes zoster 31.5 IL2 IL10 IFNG IFNA1 HLA-B HCP5
37 myelitis 31.5 TNF IL6 IL10
38 respiratory failure 31.5 TNF IL6 IL2 IL1B IL10 IFNG
39 myocarditis 31.5 TNF IL6 IL2 IL1B IL10 IFNG
40 uveitis 31.5 TNF IL6 IL2 IL1B IL10 IFNG
41 pancytopenia 31.5 IL6 IFNG CSF2 CD4 ALB
42 neutropenia 31.5 TNF IL6 IL2 IL1B IL10 IFNG
43 aplastic anemia 31.5 TNF IL6 IL1B IL10 IFNG CSF2
44 cholangitis 31.5 TNF IL6 IL2 IL10 HLA-B CCR5
45 pericardial effusion 31.5 TNF IL6 CD4 ALB
46 pericarditis 31.4 TNF IL6 IL1B IFNG
47 lymphoma, non-hodgkin, familial 31.4 IL6 IL2 CSF2 CD4 B2M
48 human immunodeficiency virus infectious disease 31.4 TNF ITIH4 IL2 IL10 IFNG IFNA1
49 exanthem 31.4 TNF IL6 IL2 IL1B IL10 IFNG
50 acute retinal necrosis syndrome 31.4 TNF IL6 IL10 CD4

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.29 ALB B2M CCR2 CCR5 CSF2 IFNG
2 endocrine/exocrine gland MP:0005379 10.23 ALB B2M CD4 CSF2 HLA-B IFNG
3 cellular MP:0005384 10.22 ALB B2M CCR2 CCR5 CD4 CSF2
4 digestive/alimentary MP:0005381 10.21 ALB B2M CCR2 CCR5 CD4 HLA-B
5 liver/biliary system MP:0005370 10.18 ALB B2M CCR2 CCR5 IFNG IL10
6 immune system MP:0005387 10.17 ALB B2M CCR2 CCR5 CD4 CSF2
7 cardiovascular system MP:0005385 10.15 ALB B2M CCR2 CCR5 CSF2 HLA-B
8 no phenotypic analysis MP:0003012 10.04 CCR2 CD4 HLA-B IFNG IL10 IL2
9 hematopoietic system MP:0005397 9.97 B2M CCR2 CCR5 CD4 CSF2 HLA-B
10 respiratory system MP:0005388 9.91 CCR2 CCR5 CSF2 IFNA1 IFNG IL10
11 mortality/aging MP:0010768 9.83 ALB B2M CCR2 CCR5 CD4 CSF2
12 integument MP:0010771 9.32 B2M CD4 CSF2 IFNG IL10 IL1B

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethambutol Approved Phase 4 74-55-5, 1070-11-7 3279 14052
2
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
3
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
4
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
5
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
6
Didanosine Approved Phase 4 69655-05-6 50599
7
Rifabutin Approved, Investigational Phase 4 72559-06-9 46783538 6323490
8
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
9
Lopinavir Approved Phase 4 192725-17-0 92727
10
Nevirapine Approved Phase 4 129618-40-2 4463
11
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
12
Aminosalicylic acid Approved Phase 4 65-49-6 4649
13
Mesalazine Approved Phase 4 89-57-6 4075
14
Fosamprenavir Approved Phase 4 226700-79-4 131536
15
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
17
Polyestradiol phosphate Approved Phase 4 28014-46-2
18
Carbamide peroxide Approved Phase 4 124-43-6
19
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
20
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
21
Rifamycin Approved, Investigational Phase 4 6998-60-3 6324616
22
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4
23
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
24
Atorvastatin Approved Phase 4 134523-00-5 60823
25
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
26
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
27
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
28
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
29
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0, 19085-09-7 4993
30
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
31
Bleomycin Approved, Investigational Phase 4 9041-93-4, 11056-06-7 5360373
32
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
33
Ethinylestradiol Approved Phase 4 57-63-6 5991
34
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
35
Lithium carbonate Approved Phase 4 554-13-2
36
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
37
Desipramine Approved, Investigational Phase 4 50-47-5 2995
38
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
39
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
40
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
41
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
43
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
44
Nicotine Approved Phase 4 54-11-5 942 89594
45
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
46
Metamfetamine Approved, Illicit, Withdrawn Phase 4 537-46-2 10836
47
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
48
Rifapentine Approved, Investigational Phase 4 61379-65-5 5462354
49
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
50
Levonorgestrel Approved, Investigational Phase 4 797-63-7 13109

Interventional clinical trials:

(show top 50) (show all 2611)
# Name Status NCT ID Phase Drugs
1 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
2 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
3 A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART Unknown status NCT02659761 Phase 4 dolutegravir/abacavir/lamivudine
4 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
5 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
6 Multicenter, Open, Pilot Clinical Trial Aimed to Compare the Efficacy of RAL1200 QD vs DRV-cb 800-150 QD Both in Combination With TAF/FTC in Patients With HIV Infection and CD4 Count Under 200 Cells/microL Unknown status NCT03842488 Phase 4 Experimental: RAL QD;Active comparator: DRV/cb
7 Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department Unknown status NCT03711253 Phase 4 Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
8 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
9 A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study Unknown status NCT04076423 Phase 4 Dual Therapy;Triple therapy
10 Impact of HIV-1 and Aging on Mucosal Vaccine Responses Unknown status NCT03729778 Phase 4
11 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
12 Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE) Unknown status NCT04249037 Phase 4 bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF);Standard initiation of antiretroviral therapy (ART)
13 Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed Unknown status NCT04132674 Phase 4 Bictegravir/emtricitabine/tenofovir alafenamide
14 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
15 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
16 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
17 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
18 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
19 The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness Unknown status NCT01264510 Phase 4
20 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
21 A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients. Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
22 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Unknown status NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
23 Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults Unknown status NCT01782950 Phase 4 Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
24 A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea Completed NCT04192487 Phase 4 Crofelemer delayed-release tablets 125mg
25 An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1. Completed NCT00144157 Phase 4 Nevirapine;Zidovudine;3TC
26 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
27 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
28 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
29 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
30 A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa. Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
31 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
32 Biomarkers for Event-driven PrEP Adherence Completed NCT04298697 Phase 4 TDF/FTC Dose Schedule for Arm A;TDF/FTC Dose Schedule for Arm B
33 A Personalized mHealth Approach to Smoking Cessation for Veterans Living With HIV (CDA 17-005) Completed NCT04135937 Phase 4 Bupropion;Varenicline;Nicotine Replacement Therapy
34 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg
35 Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial Completed NCT00795717 Phase 4 Lovaza;Placebo
36 An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function Completed NCT00717067 Phase 4 Maraviroc;Ritonavir;Saquinavir
37 Phase IV, Single-center, Open Study to Evaluate the Benefits of the Start of Immediate Treatment Without Immunovirological Data ("Same Day Treatment") Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection Completed NCT05606055 Phase 4 BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
38 A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa Completed NCT02028676 Phase 4 Arm A: ABC+3TC+NNRTI;Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance;Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance;Once-daily ABC+3TC;Twice-daily ABC+3TC;Continued cotrimoxazole prophylaxis
39 An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects Completed NCT02634073 Phase 4 Lamivudine;Sorbitol
40 Strategic Timing of AntiRetroviral Treatment Completed NCT00867048 Phase 4 All licensed antiretroviral medications
41 A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection Completed NCT00843713 Phase 4 raltegravir;Placebo
42 Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection Completed NCT00801879 Phase 4 Mupirocin calcium ointment, 2%;Placebo ointment
43 Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus Completed NCT02761629 Phase 4 Peg-Interferon Alpha-2A;Ribavirin
44 An Open-Label Safety Trial of Enfuvirtide (T-20/RO 29-9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiviral Regimen in Thai Patients With Advanced HIV Infection Completed NCT02582983 Phase 4 Enfuvirtide
45 Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects Completed NCT00549198 Phase 4 Abacavir/lamivudine and efavirenz;Tenofovir/Emtricitabine and efavirenz
46 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed NCT01869634 Phase 4 darunavir with ritonavir and fixed-dose viread+emtricitabine daily
47 A Randomized Comparative Clinical Trial of ZDV + 3TC + ABC (Trizivir) vs Monotherapy With Lopinavir/R (Kaletra) in Patients With Viral Suppression on Previous Treatment With ZDV + 3TC + ABC (Trizivir) for Preventing Lipoatrophy Completed NCT00865475 Phase 4 AZT+3TC+ABV (Trizivir);Switching to LPV/r monotherapy (Kaletra)
48 A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir Completed NCT00865007 Phase 4 Monotherapy (Lopinavir/ritonavir);Monotherapy (Lopinavir/ritonavir) + ABC/3TC
49 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
50 Lopinavir/r Plus Saquinavir Salvage Therapy in HIV-infected Children With NRTI and/or NNRTI Failure: PK and Two-year Treatment Follow up Completed NCT00476359 Phase 4 Lopinavir/r plus saquinavir

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


abacavir
abacavir sulfate
Amprenavir
Delavirdine
Delavirdine Mesylate
Didanosine
efavirenz
enfuvirtide
Immunoglobulins, Intravenous
Indinavir
Indinavir Sulfate
Lamivudine
lopinavir
Nelfinavir
Nelfinavir Mesylate
Nevirapine
Ritonavir
Saquinavir
saquinavir mesylate
Stavudine
Tenofovir
tenofovir alafenamide fumarate
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine

Cochrane evidence based reviews: acquired immunodeficiency syndrome

Genetic Tests for Acquired Immunodeficiency Syndrome

Anatomical Context for Acquired Immunodeficiency Syndrome

Organs/tissues related to Acquired Immunodeficiency Syndrome:

MalaCards : T Cells, Breast, Bone Marrow, Lymph Node, Brain, Liver, Bone

Publications for Acquired Immunodeficiency Syndrome

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 49505)
# Title Authors PMID Year
1
Effects of marriage equality legislation on sexual health of the US population. 62
36165350 2023
2
Short-term exposure to ambient particulate matter and mortality among HIV/AIDS patients: Case-crossover evidence from all counties of Hubei province, China. 62
36257445 2023
3
High prevalence of vitamin D deficiency in HIV-infected individuals in comparison with the general population across Punjab province, Pakistan. 62
36387030 2023
4
Cachexia Is Associated With Adverse Outcomes in Patients Admitted With Heart Failure. 62
36343443 2023
5
U.S. Leading Causes of Death and Years of Potential Life Lost, 1981-2019: Implications for Surgical Research. 62
35945037 2023
6
Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis. 62
36112847 2022
7
FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation. 62
36285453 2022
8
International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. 62
36319943 2022
9
Detection of Bartonella vinsonii subsp. berkhoffii in an HIV patient using metagenomic Next-Generation Sequencing. 62
35736664 2022
10
Novel 2-(Diphenylmethylidene) Malonic Acid Derivatives as Anti-HIV Agents: Molecular Modeling, Synthesis and Biological Evaluation. 62
35765501 2022
11
HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis. 62
35016590 2022
12
Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus. 62
36279805 2022
13
Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease. 62
36464783 2022
14
Risk factors for depressive symptoms by age group among human immunodeficiency virus-infected adults in Korea. 62
34612099 2022
15
Acquired immunodeficiency syndrome complicating calvarial tuberculosis. 62
35710516 2022
16
Professional commitment and willingness to care for people living with HIV among undergraduate nursing students: The mediating role of empathy. 62
36306636 2022
17
Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication. 62
35132924 2022
18
Changes and Treatment Prognosis of Aqueous Humor Cytokine Concentrations of Patients with Acquired Immune Deficiency Syndrome Complicated by Cytomegalovirus Retinitis. 62
36378859 2022
19
Lymphopenia in sepsis-an acquired immunodeficiency? 62
36468797 2022
20
Antiretroviral Therapy Management in Adults With HIV During ICU Admission. 62
33858244 2022
21
Atypical Presentation of Progressive Disseminated Histoplasmosis in a Patient Recently Diagnosed with Acquired Immunodeficiency Syndrome (AIDS). 62
36462572 2022
22
Pituitary Abscess Causing Hypopituitarism in a Patient With Acquired Immunodeficiency Syndrome. 62
36447827 2022
23
Ocular toxoplasmosis in a patient with acquired immunodeficiency syndrome. 62
36395783 2022
24
Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. 62
36323643 2022
25
Dupilumab for the treatment of adult atopic dermatitis in special populations. 62
35829641 2022
26
Oral and maxillofacial manifestations of human immunodefficiency virus infection. 62
35618625 2022
27
Comprehensive HIV/AIDS knowledge and safer sex negotiation among adolescent girls and young women in sub-Saharan Africa. 62
34558397 2022
28
Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. 62
36359329 2022
29
Prediction of HIV-1 protease cleavage site from octapeptide sequence information using selected classifiers and hybrid descriptors. 62
36344934 2022
30
Spatial analysis of the AIDS mortality rate among young people in a province of the Brazilian Amazon: An ecological study. 62
36468598 2022
31
Molecular Dynamics Study on Selected Bioactive Phytochemicals as Potential Inhibitors of HIV-1 Subtype C Protease. 62
36422295 2022
32
The Medication Experience of TB/HIV Coinfected Patients: Qualitative Study. 62
36429870 2022
33
Association of asthma and herpes zoster, the role of vaccination: A literature review. 62
36301037 2022
34
Microfluidic Devices for HIV Diagnosis and Monitoring at Point-of-Care (POC) Settings. 62
36354458 2022
35
[Fatal neurological side effect of anti-CD20 antibody treatment]. 62
36422661 2022
36
Spatial variability of mother-to-child human immunodeficiency virus transmission in a province in the Brazilian Rainforest: An ecological study. 62
36468599 2022
37
Neuropsychological deficits associated with medical conditions: Implications for psychological services in criminal legal settings. 62
35298234 2022
38
Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report. 62
36345027 2022
39
Kaposi Varicelliform Eruption With Contact Dermatitis in a Person Living with AIDS. 62
36113460 2022
40
Could Vhavenda initiation schools be a panacea for HIV and AIDS management in the Vhembe district of South Africa? 62
36453819 2022
41
Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study. 62
36354676 2022
42
Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. 62
35165230 2022
43
Consolidated Overview of Notifiable Adverse Events in the U.S. President's Emergency Plan for AIDS Relief's Voluntary Medical Male Circumcision Program Through 2020. 62
36348185 2022
44
Hearing more to hear less: a scoping review of hearing aids for tinnitus relief. 62
34865589 2022
45
Patterns of HIV or AIDS Mortality Among Older People From 1990 to 2019 in China: Age-Period-Cohort Analysis. 62
36394944 2022
46
Strengths and Challenges of Implementing a Learning Collaborative in the Ryan White HIV/AIDS Program. 62
34142596 2022
47
Sexual Enrichment Aids: A Mixed Methods Study Evaluating Use, Hygiene, and Risk Perception among Women. 62
34919465 2022
48
Comprehensive HIV/AIDS knowledge and HIV testing among men in sub-Saharan Africa: a multilevel modelling. 62
34736542 2022
49
Attrition rate and its predictors among adults receiving anti-retroviral therapy following the implementation of the "Universal Test and Treat strategy" at public health institutions in Northern Ethiopia. A retrospective follow-up study. 62
36411907 2022
50
Survival time and predictors of death among HIV infected under five children after initiation of anti -retroviral therapy in West Amhara Referral Hospitals, Northwest Ethiopia. 62
36411424 2022

Variations for Acquired Immunodeficiency Syndrome

Expression for Acquired Immunodeficiency Syndrome

Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.

Pathways for Acquired Immunodeficiency Syndrome

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 B2M CCR2 CCR5 CD4 CSF2 HLA-B
2
Show member pathways
13.85 CCR2 CCR5 CD4 CSF2 IL10 IL1B
3
Show member pathways
13.68 CCR2 CCR5 CD4 CSF2 IFNA1 IFNG
4
Show member pathways
13.57 TNF IL6 IL2 IL1B IL10 IFNG
5
Show member pathways
13.48 CCR2 CCR5 CD4 CSF2 IL10 IL1B
6
Show member pathways
13.37 CCR2 CCR5 CD4 CSF2 IL10 IL1B
7
Show member pathways
13.26 B2M CCR2 CCR5 CD4 CSF2 HLA-B
8
Show member pathways
12.86 TNF IL6 IL2 IL1B IFNA1
9
Show member pathways
12.71 CCR5 CD4 IFNG IL1B TNF
10
Show member pathways
12.7 TNF IL6 IL2 IL1B IL10 IFNG
11 12.66 TNF IL2 IL1B IL10 IFNG IFNA1
12
Show member pathways
12.66 CCR2 CCR5 HLA-B IFNA1 IFNG IL10
13
Show member pathways
12.53 TNF IL6 IL1B IFNA1
14
Show member pathways
12.43 TNF IL6 IL1B IFNG
15
Show member pathways
12.34 TNF IL6 IL1B IFNG
16
Show member pathways
12.29 TNF IL2 IFNG HLA-B CSF2
17
Show member pathways
12.26 TNF IL2 IL10 IFNG CSF2 CD4
18 12.21 TNF IL6 IL1B IL10
19 12.21 TNF IL6 IL1B IL10 IFNG
20 12.12 TNF IL6 IL2 IL1B IFNG CCR2
21
Show member pathways
12.1 IL2 IL1B IFNG CD4 CCR5 B2M
22 12.04 TNF IL6 IL2 IL10 IFNG CSF2
23 12.03 IL10 IL1B IL6 TNF
24 12 HLA-B IFNG IL10 IL1B IL2 TNF
25 11.97 IL6 IL10 CCR5 CCR2
26
Show member pathways
11.95 IL6 IL1B IFNG CD4
27
Show member pathways
11.95 TNF IL6 IL2 IL1B IL10 IFNG
28 11.92 TNF IL2 IL1B IL10 IFNG CD4
29 11.88 IL6 IFNG IFNA1
30 11.87 IL6 IL2 IFNG CSF2
31 11.86 CCR5 CD4 IFNG IL10 IL2 IL6
32 11.85 CSF2 IFNG IL10 IL2 IL6
33 11.85 CD4 IFNG IL1B IL2 IL6
34 11.82 TNF NEAT1 IL6 IL2 IL10 IFNG
35
Show member pathways
11.81 TNF IL1B IFNG
36
Show member pathways
11.8 TNF IL2 IFNG CSF2
37 11.8 TNF IL6 IL1B CSF2 CCR2
38 11.78 TNF IL6 IL1B
39 11.77 TNF IL6 IL1B IL10
40
Show member pathways
11.76 IFNG IL10 IL2 IL6 TNF
41
Show member pathways
11.75 TNF IL6 IL2 IL1B IFNG CSF2
42 11.69 TNF IL6 IL10
43 11.64 TNF IL1B IFNG CCR2
44 11.64 TNF IL2 IL10 IFNG CD4
45 11.63 IL6 IL2 IFNG
46 11.62 IL2 IL10 IFNG CD4
47 11.6 TNF IL10 CSF2
48 11.6 TNF IL6 IFNG
49 11.6 TNF IL6 IL1B IFNG
50
Show member pathways
11.52 TNF IL2 IL10 IFNG CSF2

GO Terms for Acquired Immunodeficiency Syndrome

Cellular components related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.64 TNF ITIH4 IL6 IL2 IL1B IL10

Biological processes related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA-binding transcription factor activity GO:0051091 10.27 TNF IL6 IL1B IL10
2 positive regulation of interleukin-6 production GO:0032755 10.23 TNF IL6 IL1B IFNG
3 calcium-mediated signaling GO:0019722 10.2 TNF CD4 CCR5 CCR2
4 positive regulation of type II interferon production GO:0032729 10.17 TNF IL2 IL1B CCR2
5 receptor signaling pathway via JAK-STAT GO:0007259 10.16 IFNG CSF2 CCR2
6 positive regulation of nitric oxide biosynthetic process GO:0045429 10.15 TNF IL1B IFNG
7 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.14 TNF IL1B CSF2
8 cellular response to lipopolysaccharide GO:0071222 10.14 CCR5 CSF2 IL10 IL1B IL6 TNF
9 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.13 TNF IL6 IL10
10 positive regulation of T cell activation GO:0050870 10.13 CD4 CCR2 B2M
11 positive regulation of interleukin-2 production GO:0032743 10.12 IL1B CD4 CCR2
12 liver regeneration GO:0097421 10.1 TNF IL6 IL10
13 positive regulation of cytokine production GO:0001819 10.1 IFNG IL10 IL1B TNF
14 regulation of insulin secretion GO:0050796 10.1 IFNG IL1B IL6 TNF
15 positive regulation of immunoglobulin production GO:0002639 10.08 IL10 IL2 IL6
16 macrophage differentiation GO:0030225 10.07 IFNG CSF2 CD4
17 defense response GO:0006952 10.06 CCR5 HLA-B IFNA1 TNF
18 positive regulation of glial cell proliferation GO:0060252 10.02 TNF IL6 IL1B
19 positive regulation of chemokine production GO:0032722 10.02 TNF IL6 IL1B IFNG
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.02 TNF IL6 IL2 IFNG CSF2
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.01 TNF IL1B IFNG
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 10 TNF IL1B IL10
23 astrocyte activation GO:0048143 9.99 TNF IL1B IFNG
24 positive regulation of NMDA glutamate receptor activity GO:1904783 9.98 IFNG CCR2
25 negative regulation of cytokine production involved in immune response GO:0002719 9.98 TNF IL10
26 positive regulation of fever generation GO:0031622 9.97 TNF IL1B
27 negative regulation of neurogenesis GO:0050768 9.97 TNF IL6 IL1B B2M
28 humoral immune response GO:0006959 9.96 TNF IL6 IFNG IFNA1 CCR2
29 regulation of vascular endothelial growth factor production GO:0010574 9.94 CCR2 IL6
30 sequestering of triglyceride GO:0030730 9.94 IL1B TNF
31 positive regulation of synoviocyte proliferation GO:1901647 9.93 NEAT1 TNF
32 positive regulation of neuroinflammatory response GO:0150078 9.93 TNF IL6 IL1B
33 positive regulation of plasma cell differentiation GO:1900100 9.92 IL2 IL10
34 positive regulation of nitrogen compound metabolic process GO:0051173 9.91 TNF IFNG
35 vascular endothelial growth factor production GO:0010573 9.91 TNF IL6 IL1B
36 positive regulation of vitamin D biosynthetic process GO:0060557 9.88 TNF IFNG
37 chronic inflammatory response to antigenic stimulus GO:0002439 9.88 TNF IL10
38 positive regulation of inflammatory response GO:0050729 9.73 TNF NEAT1 IL2 IL1B IFNG CCR2
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 IFNG IL1B TNF
40 immune response GO:0006955 9.6 TNF IL6 IL2 IL1B IL10 IFNG

Molecular functions related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.53 TNF IL6 IL2 IL1B IL10 IFNG

Sources for Acquired Immunodeficiency Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....